Try our Advanced Search for more refined results
Life Sciences
-
April 01, 2026
Harvard Researcher Can Get Docs On Prosecution Motives
A Massachusetts federal judge ruled Wednesday that a Harvard Medical School researcher and Russian national charged with smuggling frog embryo specimens can see emails and other documents regarding the government's decision to prosecute her, citing evidence the case was "vindictive."
-
April 01, 2026
Astellas Beats $115M Milestone Claim In Del. Chancery Ruling
A Delaware Court of Chancery judge has ruled that Astellas Pharma Inc. is not obligated to pay up to $115 million in disputed drug development milestone payments tied to its acquisition of Potenza Therapeutics Inc., finding that the clinical trials at issue never met the contract's definition of a Phase II study.
-
April 01, 2026
Mass. Cannabis Businesses Say Repeal Bid Misleads Voters
A coalition of Massachusetts cannabis business owners Wednesday challenged the constitutionality of a proposal to repeal retail marijuana legalization at the ballot box this November.
-
April 01, 2026
PBM Opioid Crisis Suit Stays In Federal Court, Judge Says
A Michigan federal judge on Tuesday denied a request from the state attorney general to remand to state court a suit accusing two pharmacy benefit managers of fueling the opioid crisis, saying the case will remain in federal court because work performed for federal and nonfederal clients cannot be separated.
-
April 01, 2026
CFO Scores $867K Win In Health Device Co. Wage Suit
A wearable health device company must pay its former chief financial officer nearly $867,000 after a Connecticut federal jury determined it stiffed him on his full wages and benefits, according to court filings.
-
March 31, 2026
Split 4th Circ. Affirms Injunction On W.Va. Drug Discount Law
A split Fourth Circuit panel sided with a trio of pharmaceutical manufacturers Tuesday that opposed a West Virginia law addressing drug delivery in the 340B program, saying the law attempted to reshape the "contractual bargain" Congress makes with private parties through its spending powers.
-
March 31, 2026
Novartis Seeks To Block New Wash. 340B Drug-Pricing Law
Novartis has called on a Washington federal judge to block a new state law it claims illegally expands the subsidies manufacturers must pay under the federal government's 340B Drug Pricing Program, arguing drugmakers will lose millions of dollars annually if the law is allowed to take effect in June.
-
March 31, 2026
Novartis Can't Nix FCA Suit Alleging MS Drug Kickbacks
Novartis must face a False Claims Act suit alleging it improperly had doctors prescribe its multiple sclerosis drug, a New York federal judge said Monday, finding the relator plausibly pled scienter by bringing evidence that the company "kept meticulous track" of how many prescriptions doctors wrote for the drug.
-
March 31, 2026
Anesthesia Parent Can't Duck Antitrust Suit, But Affiliate Can
The parent company of U.S. Anesthesia Partners Inc. remains in the crosshairs of a private antitrust suit accusing it of trying to monopolize Texas anesthesia services, while a federal judge dismissed for now claims against an affiliate that he said was too far removed from the alleged rollup strategy.
-
March 31, 2026
Moderna, Pfizer Want Bayer's COVID-Shot Patent Suits Tossed
Pharmaceutical giants Moderna and Pfizer-BioNTech have asked a Delaware federal judge to dismiss lawsuits seeking to recover royalties from sales of their respective COVID-19 vaccines, which plaintiff Bayer claims were made possible via infringement of its patent.
-
March 31, 2026
BioPharma Spoofing Suit Against Canadian Banks Proceeds
A New York federal judge has ruled that Quantum BioPharma Ltd. can pursue most of its lawsuit accusing the brokerage arms of the Royal Bank of Canada and the Canadian Imperial Bank of Commerce of spoofing the biopharmaceutical company's stock, finding that Quantum plausibly alleged that the scheme occurred and that the banks acted recklessly.
-
March 31, 2026
Full Fed. Circ. Is Told Panel Defied EcoFactor In DePuy Case
DePuy Synthes is urging the full Federal Circuit to review a circuit panel's decision reviving patent infringement litigation against it, saying the panel majority undermined the court's en banc EcoFactor decision on when to admit expert testimony.
-
March 31, 2026
Biogen Paying $5.6B For Apellis As 4 Firms Advise
Biogen Inc. said Tuesday that it has agreed to acquire Apellis Pharmaceuticals Inc. in a cash transaction valued at about $5.6 billion, with four law firms steering the transaction focused on key therapies for kidney and eye disorders.
-
March 31, 2026
Beasley Allen Seeks Stay Of DQ In Federal J&J Talc MDL
The Beasley Allen Law Firm asked a New Jersey federal court on Monday to hold off on disqualifying it from talc litigation against Johnson & Johnson while it appeals the disqualification order which it called "unprecedented and incorrect."
-
March 31, 2026
Insurer Says Yale Was 'Misleading' In $4.1M Transplant Claim
A Liberty Mutual unit accused Yale University's health system of making "serious and material misstatements" about a plan member's bone marrow transplant, the insurer said in its answer and counterclaim for a declaratory judgment that it can continue to deny the $4.1 million claim.
-
March 31, 2026
Kirkland, Goodwin Steer Lilly $7.8B 'Sleep-Wake' Disorder Deal
Pharmaceutical giant Eli Lilly & Co., advised by Kirkland & Ellis LLP, announced plans Tuesday to acquire daytime sleepiness-focused pharmaceutical company Centessa Pharmaceuticals PLC, led by Goodwin Procter LLP, in a deal worth up to $7.8 billion.
-
March 31, 2026
Cancer Vaccine Developer Files Ch. 7 After Trials Fall Short
A Denmark-based biotechnology firm filed for Chapter 7 liquidation Tuesday in Delaware with more than $10 million in debt after its prospective cancer vaccine failed to measure up under testing and win regulatory approval last year.
-
March 30, 2026
Don't Set Special IP Rules For 'Skinny Labels,' Justices Told
Drugmakers, industry groups, hospitals and scholars have urged the U.S. Supreme Court to uphold a decision letting a patent suit proceed over a generic drug using a so-called skinny label, saying the generics company is seeking unwarranted special protections that would upend patent law.
-
March 30, 2026
FCA Qui Tams Are Unconstitutional, Eli Lilly Tells Justices
The False Claims Act's whistleblower provisions are unconstitutional, drugmaker Eli Lilly has told the U.S. Supreme Court, asking it to overturn a Seventh Circuit decision upholding a $183 million trial win for a whistleblower who claimed the drug company hid how much it charged for Medicaid-covered drugs.
-
March 30, 2026
Sanofi Claims IP Life Extension Needed For Double Patenting
The Patent Trial and Appeal Board rightly found a Sanofi patent application shouldn't be rejected for obviousness-type double patenting, as it doesn't improperly extend patent life, the French drugmaker and its allies have told U.S. Patent and Trademark Office Director John Squires.
-
March 30, 2026
Cleary-Led Blackstone Wraps Record $6.3B Life Sci Fund
Private equity giant Blackstone, led by Cleary Gottlieb Steen & Hamilton LLP, revealed Monday that it wrapped its sixth life sciences fund after securing $6.3 billion of capital commitments, marking what the firm says is the largest private life sciences fund ever raised.
-
March 30, 2026
Eli Lilly's $2.75B Pact Is Latest In AI Drug Discovery Push
Eli Lilly and Co. has agreed to a partnership with artificial intelligence-driven drug discovery company Insilico that could be worth up to $2.75 billion, amid an expanding category of collaboration fueled by pharmaceutical giants seeking accelerated paths to new treatments.
-
March 30, 2026
Del. Judge Upholds $34M Verdict In Glaucoma Patent Feud
A Delaware federal judge has affirmed a $34 million verdict against Alcon and related entities for infringing patents covering medical devices to treat glaucoma, disagreeing that Sight Sciences Inc. had failed to show the accused product meets the limitations of the patent claims.
-
March 30, 2026
J&J Unit Wants Forensic Exam Of Ex-Director's Devices
A Johnson & Johnson subsidiary urged a New Jersey federal court to order a former associate director to submit to a court-supervised forensic inspection of any device or account in which she could have stored confidential information it claims she downloaded in order to start her own competing company.
-
March 30, 2026
Eagle Pharma To Pay $9.5M To End Channel Stuffing Claims
Eagle Pharmaceuticals Inc. and its former executives have agreed to pay $9.5 million to settle investor claims that they carried out a fraudulent "channel stuffing" scheme to inflate the revenue of one of the company's brand-name medications.
Expert Analysis
-
Record FCA Recoveries Signal Intensified Healthcare Focus
In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.
-
Fed. Circ. In Jan.: On The Validity Of Expert Testimony
The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.
-
Calif.'s Civility Push Shows Why Professionalism Is Vital
The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.
-
A Potential Shift In FDA's Approach To Drug Trial Design
Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.
-
Series
Trivia Competition Makes Me A Better Lawyer
Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.
-
What FDA Guidance Means For Future Of Health Software
Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.
-
Opinion
Federal Preemption In AI And Robotics Is Essential
Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.
-
Series
Law School's Missed Lessons: What Cross-Selling Truly Takes
Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.
-
Drafting Tech Patents After USPTO's Eligibility Memos
Two recent U.S. Patent and Trademark Office memos on subject matter eligibility declarations provide an evidentiary playbook for artificial intelligence and software patent applications, highlighting how targeted, stand‑alone SMEDs that present objective, claim‑anchored facts can improve patent application outcomes, say attorneys at Reed Smith.
-
How State FCA Activity May Affect Civil Fraud Enforcement
A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.
-
Series
Judges On AI: Practical Use Cases In Chambers
U.S. Magistrate Judge Allison Goddard in the Southern District of California discusses how she uses generative artificial intelligence tools in chambers to make work more efficient and effective — from editing jury instructions for clarity to summarizing key documents.
-
Assessing Compliance Risks Around TrumpRx Participation
As there are novel compliance obligations and potential political opposition related to the new TrumpRx online drug platform, companies intending to participate on the site should consider the pressure points that are likely to draw enforcement scrutiny, say attorneys at Sheppard.
-
USPTO Initiatives May Bolster SEP Litigation In The US
The U.S. Patent and Trademark Office's recent efforts to revitalize standard-essential patent litigation face hurdles in their reliance on courts and other agencies, but may help the U.S. regain its central role in global SEP litigation if successful, say attorneys at Axinn.
-
Series
Trail Running Makes Me A Better Lawyer
Navigating the muddy, root-filled path of trail marathons and ultramarathons provides fertile training ground for my high-stakes fractional general counsel work, teaching me to slow down my mind when the terrain shifts, sharpen my focus and trust my training, says Eric Proos at Next Era Legal.
-
Predicting Actual Impact From CDC's New Vaccine Guidance
Recent federal changes to the childhood immunization schedule, reducing the number of vaccine recommendations from 18 to 11, do not automatically create enforceable obligations for parents, schools or healthcare providers, but may spur litigation and other downstream effects on school policies and state guidelines, says Mehdi Sinaki at Michelman & Robinson.